USA flag logo/image

An Official Website of the United States Government

Targeting a new GPCR to treat glioblastomas

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43CA165452
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
PA11-096
Small Business Information
STELLA THERAPEUTICS, INC
720 Broadway Suite 411 SEATTLE, WA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Targeting a new GPCR to treat glioblastomas
Agency: HHS
Contract: 1R43CA165452-01A1
Award Amount: $291,952.00
 

Abstract:

DESCRIPTION (provided by applicant): There is an urgent need for novel therapies to treat malignant astrocytomas, the most common and aggressive primary tumor of the nervous system. Using current standard of care, patients diagnosed with these tumors havean average life expectancy of 18 months and there is no effective treatment available. The laboratory of Dr. Nephi Stella recently discovered a new subclass of indole compounds that activate GPR124, a GPCR with established relevance in tumor pathogenesis.These indoles demonstrate efficacy in both in vitro and in vivo rodent models of malignant astrocytomas. Notably, the therapeutic effective doses of indoles do not produce overt toxicity in mice. The goal of Stella Therapeutics is to develop drugs that target GPR124 and efficiently treat malignant astrocytomas with minimal side-effects. In this proof-of-concept work, we will: Aim 1: Validate an in vitro assay tha measures the potency of GPR124 agonists in human astrocytoma cells. Use this assay to screen 40analogues of NMP-192 (EC50 = 54 nM). Aim 2: Select the 2 most promising compounds and establish their pharmacokinetic and acute toxicity profiles in mice, as well as measure their in vivo efficacy in a xenograft mouse model of malignant astrocytomas. Bythe end of this Phase I SBIR, Stella Therapeutics will have developed a lead compound that activates GPR124, exhibits in vivo efficacy and induces minimal side effects. The resulting phase II SBIR will further optimize the drug-like properties of the leadcompound by using state-of-the-art medicinal chemistry and chemo-informatics. We will systematically measures their therapeutic efficacy and side effects to establish a therapeutic index. Stella Therapeutics is dedicated to developing and patenting novel drug-based therapies to treat malignant tumors. PUBLIC HEALTH RELEVANCE: There is an urgent need for novel therapies to treat malignant astrocytomas, the most common and aggressive primary tumor of the nervous system. This phase I SBIR outlines a strategy to develop a new therapeutic approach to treat these tumors. By combining the strength of several state-of-the-art approaches in drugs development, we will develop small molecules that activate a novel therapeutic target expressed by malignant astrocytomas. Stella Therapeutics is dedicated to developing and patenting novel drug-based therapies to treat malignant tumors.

Principal Investigator:

Eric A. Horne
206-579-7844
stellathera.eh@gmail.com

Business Contact:

Nephi Stella
206-579-7844
stellathera@gmail.com
Small Business Information at Submission:

STELLA THERAPEUTICS, LLC
720 Broadway Suite 411 SEATTLE, WA -

EIN/Tax ID: 127543549
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No